BREAKING
Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 12 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 12 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 15 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 17 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 19 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 21 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 23 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 24 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 1 day ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 1 day ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 12 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 12 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 15 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 17 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 19 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 21 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 23 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 24 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 1 day ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 1 day ago
ADVERTISEMENT
Earnings

CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline

$CVS February 10, 2026 2 min read

Healthcare solutions company CVS Health Corporation (NYSE: CVS) on Monday reported an increase in revenues for the fourth quarter of fiscal 2025. Meanwhile, adjusted earnings declined during the quarter.

Fourth-quarter revenues rose 8.2% to $105.7 billion from $97.7 billion in the corresponding quarter last year, driven by growth across all operating segments.
Earnings, adjusted for special items, declined to $1.09 per share from $1.19 per share in the year-ago quarter. Unadjusted net income was $2.92 billion or $2.30 per share in Q4, compared to $1.63 billion or $1.30 per share in the fourth quarter of 2024.

For fiscal 2025, management continues to expect earnings in the range of $5.94 per share to $6.14 per share. It also reaffirmed the guidance for full-year adjusted earnings per share in the $7.00 -$7.20 range. The forecast for cash flow from operations has been revised to at least $9.0 billion from the previous guidance of $10.0 billion.

“Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America,” said David Joyner, the company’s CEO.

ADVERTISEMENT